With ongoing advances in antiviral therapies, chronic hepatitis B management has entered a new era of effective viral suppression, where complete virological response and functional cure are realistic goals.
In this context, precise and highly sensitive HBV DNA quantification is essential for treatment monitoring, evidence-based treatment discontinuation decisions, and progress toward clinical cure.
Supbio has developed an HBV DNA quantitative detection kit with ultra-high sensitivity and precise quantification capability. The assay enables reliable detection of extremely low viral loads and early identification of residual viremia. It supports long-term antiviral therapy management for chronic hepatitis B and plays a critical role in evaluating treatment response, guiding safe treatment discontinuation, and monitoring relapse risk.
Through continuous innovation in molecular diagnostics, Supbio is committed to advancing personalized and precision treatment for chronic hepatitis B. Our diagnostic solutions help physicians and patients better assess treatment effectiveness, determine readiness for treatment cessation, and move closer to achieving the goal of HBV cure.
